Richards, Merrill & Peterson, Inc. Spero Therapeutics, Inc. Transaction History
Richards, Merrill & Peterson, Inc.
- $191 Billion
- Q4 2024
A detailed history of Richards, Merrill & Peterson, Inc. transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Richards, Merrill & Peterson, Inc. holds 150 shares of SPRO stock, worth $122. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150Holding current value
$122% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SPRO
# of Institutions
56Shares Held
15.7MCall Options Held
200Put Options Held
200-
Anson Funds Management LP Dallas, TX3.84MShares$3.15 Million0.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.76MShares$1.45 Million0.0% of portfolio
-
Atlas Venture Associates Ix, LLC Boston, MA1.35MShares$1.11 Million14.54% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.11MShares$906,5840.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.04MShares$852,7360.0% of portfolio
About Spero Therapeutics, Inc.
- Ticker SPRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,067,500
- Market Cap $28.8M
- Description
- Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...